Pediatr Blood Cancer
Antineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicCytarabine
Dr. Christopher Jon Forlenza, MD
NPI1467751560
- Publications
- 31
- Clinical trials
- 12
- Hospital affiliations
- 1
- Industry payments
- $3,454
- Medical group
- 1
- Practice address
- 1275 York Avenue, New York, NY 10065
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Find Dr. Forlenza's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Christopher Jon Forlenza is a pediatric hematology and oncology physician in New York, New York
Dr. Forlenza practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.
Dr. Forlenza's NPI, 1467751560, was assigned on March 15, 2011. Dr. Forlenza graduated from New York University School of Medicine in 2008. Dr. Forlenza holds New York license 260552-01.
NPI and contact details
- NPI
- 1467751560NPI Registry (opens in a new tab)
- NPI enumeration date
- March 15, 2011
- NPI status
- Active
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Male
- Estimated age
- 44
- Medical school graduation
- 2008
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Affiliation Data
Dr. Christopher Jon Forlenza practices at Memorial Sloan Kettering Cancer Center in New York, New York
Dr. Forlenza's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.
- Memorial Sloan Kettering Cancer Center1275 York Avenue, New York, NY 10065
Source: Dmand AI Affiliation Data
Dr. Christopher Jon Forlenza is affiliated with 1 site of care and 1 medical group
Dr. Forlenza's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center (MSK Kids).
Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data
Dmand AI tracks the EHR system at Dr. Christopher Jon Forlenza's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Forlenza practices. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Memorial Sloan Kettering Cancer Center | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
See the EHR and IT leaders at every hospital where Dr. Forlenza practices
Dmand AI maps EHR vendors, IT decision makers and buying committees across Memorial Sloan Kettering Cancer Center and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Christopher Jon Forlenza is one of 232 pediatric hematologys and oncology physicians in New York
Pediatric hematology-oncology is Dr. Forlenza's primary specialty in the NPI Registry, under taxonomy code 2080P0207X. Dr. Forlenza is board certified in pediatric hematology-oncology by the American Board of Pediatrics. Dmand AI has Dr. Forlenza's licenses on file in 2 states: New York and Florida.
Specialties and state licenses
- Pediatric hematology and oncology, New YorkPrimary
- Florida license
Pediatric hematologys and oncology physicians near Dr. Forlenza
Counts of pediatric hematologys and oncology physicians with a Dmand AI profile, by place and practice. Each opens the list.
232pediatric hematologys and oncology physicians in New York96pediatric hematologys and oncology physicians in New York29pediatric hematologys and oncology physicians at Memorial Sloan Kettering Cancer Center
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Christopher Jon Forlenza's patients have a median age of 7
Across all payers, Dmand AI patient panel data puts Dr. Forlenza's median patient age at 7, with 34% women.
Dr. Forlenza's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 7
Patient panel by sex, all payers
- Women34%
- Men66%
Source: Dmand AI Patient Panel Data
Dr. Christopher Jon Forlenza has 31 publications on record
Dmand AI links 31 papers to Dr. Forlenza, published from 2012 to 2025. 2018 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Hodgkin Disease and Brentuximab Vedotin. Dr. Forlenza has published most often in Blood Adv. Dr. Forlenza's most frequent co-authors are Peter G. Steinherz, MD, Neerav Narendra Shukla, MD and Nancy A. Kernan, MD.
Papers31
Years published2012 to 2025
Dr. Forlenza's papers by year, 2015 to 2025
Topics Dr. Forlenza writes about most
- Antineoplastic Combined Chemotherapy Protocols
- Hodgkin Disease
- Brentuximab Vedotin
- Hematopoietic Stem Cell Transplantation
- Drug Resistance, Neoplasm
- Leukemia, Myeloid, Acute
- Vincristine
- Antigens, CD19
Dr. Forlenza's most frequent co-authors
- Peter G. Steinherz, MD8 shared papers
- Neerav Narendra Shukla, MD7 shared papers
- Nancy A. Kernan, MD4 shared papers
Recent publications by Dr. Forlenza
Pediatr Blood Cancer
Antineoplastic Combined Chemotherapy ProtocolsAsparaginaseBridged Bicyclo Compounds, Heterocyclic
J Pediatr Hematol Oncol
Antineoplastic Combined Chemotherapy ProtocolsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Genetic TestingGerm-Line MutationHematologic Neoplasms
See who Dr. Forlenza researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Forlenza works with, so you can find a warm path to the right pediatric hematologys and oncology physicians.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Christopher Jon Forlenza has worked on 12 clinical trials
Dmand AI links Dr. Forlenza to 12 clinical trials, 7 of them phase 2 studies. 11 are still active or recruiting. Conditions studied include Histiocytosis, Langerhans-Cell, Hepatoblastoma and Hodgkin Disease. National Cancer Institute (NCI) sponsors the most, 10.
Clinical trials with Dr. Forlenza by phase
- NonePhase 1: no trials
- 1Phase 1/2: 1 trial
- 7Phase 2: 7 trials
- 1Phase 2/3: 1 trial
- 3Phase 3: 3 trials
- NonePhase 4: no trials
Conditions in Dr. Forlenza's trials
- Histiocytosis, Langerhans-Cell
- Hepatoblastoma
- Hodgkin Disease
- Leukemia, Myeloid, Chronic-Phase
- Pheochromocytoma
Investigators on the most trials with Dr. Forlenza
- Erin Haag Breese, MD6 shared trials
- Margaret E. Macy, MD6 shared trials
- Jean M. Tersak, MD6 shared trials
Recent clinical trials with Dr. Forlenza
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (opens in a new tab)
Active, not recruitingPhase 3
NivolumabCyclophosphamideDoxorubicin Hydrochloride
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial (opens in a new tab)
Active, not recruitingPhase 2
Histiocytosis, Langerhans-CellHepatoblastomaSelpercatinib
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial (opens in a new tab)
Active, not recruitingPhase 2
PheochromocytomaHistiocytosis, Langerhans-CellTipifarnib
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) (opens in a new tab)
Active, not recruitingPhase 2
Histiocytosis, Langerhans-CellHepatoblastomaIvosidenib
An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) (opens in a new tab)
CompletedPhase 2/3
Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, LymphoidIM JZP-458IV JZP-458
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Christopher Jon Forlenza received $3,454 in industry payments from 2019 to 2024
CMS Open Payments shows 11 general payments to Dr. Forlenza from 3 drug and device companies from 2019 to 2024. Consulting fees make up the largest share, 71% of the total. Bristol-Myers Squibb Company paid the most, $2,436.
General payments to Dr. Forlenza by program year, 2019 to 2024
General payments to Dr. Forlenza by kind, 2019 to 2024
$3.5Kin total
- Consulting fees$2,43671%
- Travel and lodging$70220%
- Food and beverage$3159%
Companies that paid Dr. Forlenza the most, 2019 to 2024
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Dr. Christopher Jon Forlenza graduated from New York University School of Medicine
Dr. Forlenza graduated from New York University School of Medicine in 2008. Dr. Forlenza is a member of Children's Oncology Group.
- Medical school
- Board certified in pediatric hematology-oncology
- Board certified in pediatrics
Source: Dmand AI Professional Profile Data
Dr. Christopher Jon Forlenza accepts plans from 9 insurance carriers
Dr. Forlenza is in network with 9 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.
- Aetna
- United Healthcare
- Blue Cross Blue Shield of Michigan
- MVP Health Care
- Aspirus Health Plan
- Blue Cross and Blue Shield of Kansas City
- Elevance
- HCSC
- +1 more carriersWith a free account
Plan types Dr. Forlenza accepts, by number of carriers
- PPO6
- POS4
- EPO3
- HMO3
- Medicare2
- Medicaid1
Source: Dmand AI Insurance Network Data
Sources for Dr. Christopher Jon Forlenza's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | Dmand AI Affiliation Data |
| Primary practice, affiliations and health system | Dmand AI Affiliation DataDmand AI Org Hierarchy Data |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel Data |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| Training, board certification and memberships | Dmand AI Professional Profile Data |
| Insurance carriers and plan types | Dmand AI Insurance Network Data |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Christopher Jon Forlenza
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Christopher Jon Forlenza's NPI number?
Dr. Christopher Jon Forlenza's NPI number is 1467751560. It was assigned on March 15, 2011, and it is active in the NPI Registry.
What kind of doctor is Dr. Christopher Jon Forlenza?
Dr. Christopher Jon Forlenza is a pediatric hematology and oncology physician in New York, New York. The primary specialty in the NPI Registry is Pediatric Hematology & Oncology Physician (taxonomy code 2080P0207X).
Where does Dr. Christopher Jon Forlenza practice?
Dr. Forlenza practices at 1275 York Avenue, New York, NY 10065. Dr. Forlenza's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.
What is Dr. Christopher Jon Forlenza's medical license number?
Dr. Forlenza holds New York license 260552-01, one of the licenses on file in 2 states.
Which states has Dr. Christopher Jon Forlenza been licensed in?
Dmand AI has state licenses on file for Dr. Forlenza in New York (2011 to 2026) and Florida (since 2021).
Which hospitals is Dr. Christopher Jon Forlenza affiliated with?
Dr. Forlenza practices at Memorial Sloan Kettering Cancer Center in New York, New York.
What medical group is Dr. Christopher Jon Forlenza part of?
Dr. Forlenza is linked to Memorial Sloan Kettering Cancer Center (MSK Kids).
Is Dr. Christopher Jon Forlenza board certified?
Yes. Dr. Forlenza is board certified in pediatric hematology-oncology by the American Board of Pediatrics.
Where did Dr. Christopher Jon Forlenza go to medical school?
Dr. Forlenza graduated from New York University School of Medicine in 2008.
Has Dr. Christopher Jon Forlenza received payments from drug or device companies?
CMS Open Payments shows $3,454 in general payments to Dr. Forlenza from 3 companies from 2019 to 2024. The largest total came from Bristol-Myers Squibb Company.
Show 4 more questionsShow fewer questions
How long has Dr. Christopher Jon Forlenza been practicing?
Dr. Forlenza graduated from medical school in 2008, 18 years ago.
Does Dr. Christopher Jon Forlenza do research?
Dmand AI links 31 publications to Dr. Forlenza, published from 2012 to 2025. Dr. Forlenza has worked on 12 clinical trials.
Who does Dr. Christopher Jon Forlenza publish with?
Dr. Forlenza's most frequent co-authors are Peter G. Steinherz, MD (8 shared papers), Neerav Narendra Shukla, MD (7 shared papers) and Nancy A. Kernan, MD (4 shared papers).
What insurance does Dr. Christopher Jon Forlenza accept?
Dr. Forlenza is in network with 9 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.
Selling to pediatric hematology-oncology practices?
See pediatric hematologys and oncology physicians in New York by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card